Summary & Overview
CPT 81418: Pharmacogenomic Drug Metabolism Genomic Sequence Analysis Panel
CPT code 81418 represents a comprehensive pharmacogenomic panel for drug metabolism, requiring analysis of at least six genes, including detailed variant and duplication/deletion analysis for CYP2C19 and CYP2D6. This code is significant nationally as it supports precision medicine by informing clinicians about individual patient responses to medications, potentially improving therapeutic outcomes and reducing adverse drug reactions. The procedure is typically performed in independent laboratories and is classified under genomic sequencing and molecular multianalyte assays.
Major payers such as Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare provide coverage for this service, reflecting its growing importance in clinical practice and payer policy. Readers will gain insights into payer coverage benchmarks, recent policy updates, and the clinical context for pharmacogenomic testing. The publication also addresses relevant coding practices, associated diagnoses, and related CPT codes, offering a comprehensive overview for stakeholders in laboratory medicine, billing, and healthcare policy.
CPT Code Overview
CPT code 81418 is used for drug metabolism genomic sequence analysis panels, specifically in the context of pharmacogenomics. This procedure involves testing at least six genes, including variant analysis for CYP2C19 and CYP2D6, as well as duplication and deletion analysis for CYP2D6. The service falls under Pathology and Laboratory Procedures – Genomic Sequencing Procedures and Other Molecular Multianalyte Assays. The typical site of service for this code is an Independent Laboratory (Place of Service 81). This testing provides valuable information for understanding how patients metabolize medications, supporting personalized medicine approaches.
Clinical & Coding Specifications
Clinical Context
A patient is referred to an independent laboratory for pharmacogenomic testing to guide drug therapy decisions. The patient has a diagnosis of a solid organ tumor, such as a renal cell carcinoma (C64.1*, C64.2*), or a neuroendocrine tumor (C7A.093*). The ordering physician requests a genomic sequence analysis panel to assess drug metabolism, specifically including at least six genes, with mandatory analysis of CYP2C19 and CYP2D6 variants, as well as CYP2D6 duplication/deletion. The results will inform medication selection and dosing, particularly for drugs metabolized by these enzymes. The laboratory performs the sequencing and reports findings to the provider, who integrates the results into the patient's treatment plan.
Coding Specifications
- Modifier
59: Indicates a distinct procedural service. Used when the drug metabolism genomic sequence analysis panel (81418) is performed separately from other procedures, ensuring proper reporting of independent services.
| Modifier Code | Description |
|---|---|
59 | Distinct procedural service |
- Associated Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207ZP0102X | Pathology - Clinical Pathology/Laboratory Medicine |
207ZP0007X | Pathology - Molecular Genetic Pathology |
207L00000X | Anatomic Pathology & Clinical Pathology |
- These taxonomies represent providers specializing in laboratory medicine, molecular genetic pathology, and anatomic/clinical pathology, who are qualified to perform and interpret genomic sequencing procedures.
Related Diagnoses
C25.4*: Malignant neoplasm of endocrine pancreas. Relevant for patients with pancreatic tumors requiring pharmacogenomic testing to guide therapy.C64.1*: Malignant neoplasm of right kidney. Indicates renal cancer, where drug metabolism testing may inform treatment.C64.2*: Malignant neoplasm of left kidney. Similar relevance as above for left-sided renal tumors.C65.1*: Malignant neoplasm of right renal pelvis. Used for patients with renal pelvis tumors.C65.2*: Malignant neoplasm of left renal pelvis. Indicates left renal pelvis involvement.C66.1*: Malignant neoplasm of right ureter. Drug metabolism testing may be relevant for chemotherapy planning.C66.2*: Malignant neoplasm of left ureter. As above, for left ureter tumors.C67.0*: Malignant neoplasm of trigone of bladder. Relevant for bladder cancer patients.C67.1*: Malignant neoplasm of dome of bladder. Indicates specific bladder tumor location.C67.2*: Malignant neoplasm of lateral wall of bladder. Used for lateral bladder tumors.C67.3*: Malignant neoplasm of anterior wall of bladder. Indicates anterior bladder involvement.C67.4*: Malignant neoplasm of posterior wall of bladder. For posterior bladder tumors.C67.5*: Malignant neoplasm of bladder neck. Indicates tumor at bladder neck.C67.6*: Malignant neoplasm of ureteric orifice. Relevant for tumors at the ureteric orifice.C67.7*: Malignant neoplasm of bladder, unspecified. Used when bladder tumor location is not specified.C67.8*: Malignant neoplasm of overlapping sites of bladder. Indicates multiple bladder sites involved.C68.0*: Malignant neoplasm of urethra. Drug metabolism testing may guide therapy for urethral tumors.C68.1*: Malignant neoplasm of paraurethral region. Indicates paraurethral involvement.C68.8*: Malignant neoplasm of overlapping sites of urinary organs. Used for tumors involving multiple urinary organs.C7A.093*: Malignant neuroendocrine tumors, other specified sites. Relevant for neuroendocrine tumor patients.D13.7*: Benign neoplasm of other specified digestive organs. Used for benign digestive organ tumors.D18.02*: Hemangioma of kidney. Indicates vascular kidney tumors.D32.0*: Benign neoplasm of cerebral meninges. Drug metabolism testing may be relevant for CNS tumor patients.D32.1*: Benign neoplasm of spinal meninges. Indicates spinal meningeal tumors.D33.0*: Benign neoplasm of brain, supratentorial. Used for supratentorial brain tumors.D33.1*: Benign neoplasm of brain, infratentorial. Indicates infratentorial brain involvement.D33.3*: Benign neoplasm of pituitary gland. Relevant for pituitary tumors.D33.4*: Benign neoplasm of craniopharyngeal duct. Indicates craniopharyngeal duct tumors.D33.7*: Benign neoplasm of other specified parts of central nervous system. Used for CNS tumors.I42.1: Obstructive hypertrophic cardiomyopathy. Drug metabolism testing may inform medication selection for cardiac patients.L20.89: Other atopic dermatitis. Relevant for patients with atopic dermatitis where pharmacogenomic testing may guide therapy.
Related CPT Codes
81225: Data not available in the input.81479: Data not available in the input.0347U: Data not available in the input.0348U: Data not available in the input.0349U: Data not available in the input.0350U: Data not available in the input.0434U: Data not available in the input.81226: Data not available in the input.0070U: Data not available in the input.
These codes are related to genomic sequencing and molecular pathology procedures. They may represent alternative panels, single gene analyses, or proprietary laboratory assays. In clinical workflow, some may be used together for comprehensive testing, while others serve as alternatives depending on the clinical indication and payer coverage.
National Reimbursement Benchmarks
National mean rates for CPT code 81418 among commercial payers are highest with Blue Cross Blue Shield at $796.12, while Cigna is lowest at $612.14. The BUCA (average commercial) mean rate is $720.33, which is higher than Cigna and Aetna but lower than Blue Cross Blue Shield. Medicare rates are not available in the input for comparison.
Rate dispersion varies significantly across payers. Cigna shows the widest spread, with a difference of $976.00 between the 75th and 25th percentiles, indicating substantial variability in reimbursement. Blue Cross Blue Shield also has a notable range of $227.30. Aetna and BUCA have tighter ranges, at $271.50 and $298.90 respectively, while UnitedHealth Group has a range of $440.00.
The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.